A R T I C L E S
Schweitzer-Stenner et al.
proteins are generally short with an average length of four
residues.8,12 A 310-helix differs from the canonical R-helix not
only with respect to its dihedral coordinates but also by a (i, i
+ 3) hydrogen-bonding arrangement.13 Augspurger et al.
investigated several Aib-based, aliphatic peptides of intermediate
size in organic solvents and obtained a very thermostable 310-
structure.14 De Filippis et al. confirmed and explained the
thermostability of Aib with the reduction of entropy of this
amino acid residue in the unfolded state.15 Numerous studies
have been conducted to identify the conditions at which Aib
stabilizes a 310-helix in peptides. Basically, a peptide gains an
extra internal hydrogen bond in a 310-helix while steric
interactions between residues favor R-helical torsional angles.
At a critical length depending on the dielectric of the solvent,
the two interactions approximately balance, and populations of
both helices coexist. For this reason, short Aib-based peptides
generally prefer 310-helices, whereas R-helices are more likely
for longer peptides.1,16,17 Rather long peptides, however, e.g.,
pBrBz-Aib10-OtBu (pBrBz, para-bromobenzyl; OtBu, tert-
butoxy) have been found to adopt 310-helices in crystals.18
Balaram et al. used NMR and electronic circular dichroism
spectroscopy to determine that the rather hydrophobic Boc-Aib-
Val-Aib2-Val3-Aib-Val-Aib-OMe and Boc-Aib-Leu-Aib2-Leu3-
Aib-Leu-Aib-OMe prefer the 310 helix in CDCl3, whereas an
R-helix preference was found in (CD3)2SO.19 This indicated that
the solvent has a strong influence due to differences in dielectric
constant and relative stabilities of hydrogen bonds on structural
preference. Crystalline forces and the choice of the protection
group have been identified as affecting the overall propensity
of Aib-based peptides in crystals.20-24 DiBlasio et al. found that
crystallized (pBrBz-Aib-(Pro-Aib)n-OMe (n ) 3, 4) forms so-
called â-ribbons which exhibit the Aib residues in 310-like
conformations.25 A review of the (mostly crystal) structure of
a large number of Aib-containing peptides by Karle and Balaram
indicated that the 310-helix is the preferred structure provided
that the fraction of Aib residues exceeds 50%.1 A dilution of
the Aib content decreases the preference for 310 so that a
coexistence of both helix types is established. Smythe et al.
calculated the potential energy landscape (i.e., potentials of mean
force) and performed molecular dynamics calculations for (Ac-
Aib10-NHMe) in Vacuo, water, and CH3CN to obtain a higher
stabilization of the R-helix for all three cases.26 The stability of
RR was found to increase with the dielectric constant of the
solvent. The higher stability of RR was later confirmed by
another computational study by Smythe et al.27 However, MD
simulations with the Cedar force field by Zhang and Hermans
yielded nearly the opposite result in that these authors obtained
310 as the predominant structure of Aib in Vacuo and a 310/RR
mixture in water.28 A strong 310 propensity of Aib was recently
experimentally confirmed by Schievano et al.29 Bu¨rgi et al. used
the GROMOS96 package to perform MD simulations for the
octapeptide Z-Aib5-Leu-Aib2-OMe in DMSO and obtained a
sampling of right- and left-handed helical conformations with
comparable fractions of R-helical and 310-conformations.30
A
somewhat different result emerged from simulations of Ma-
hadevan et al. for Aib10 in DMSO and water, for which the
authors used the CHARMM22 force field.31 They observed a
mixture of R- and π-helix. Taken together, this review of the
literature leads to the conclusion that more experimental data
are required to obtain the RR- and 310-propensity of Aib in
peptides as well as the use of force fields that include multipole
electrostatics and polarizability in MD simulations.32
In spite of some earlier work on short peptides, the intrinsic
propensity of Aib as a guest in a natural host system has not
yet been thoroughly investigated experimentally. Winter, Jung
and colleagues reported the structure of crystallized Ac-Ala-
Aib-Ala-OMe, Boc-Ala-Aib-Ala-OMe, and Boc-Gly-Ala-Aib-
OMe.33-35 For the two Ala-Aib-Ala peptides the authors
identified a distorted â-turn. CD and NMR data indicate that
this structure was maintained in DMSO for Boc-Ala-Aib-Ala-
OMe. The crystal structure of Ac-Ala-Aib-Ala-OMe was of
interest because the reported dihedral angles suggested that the
central Aib adopts a 310-like conformation, whereas the two
alanines exhibited a polyproline II (PPII)-like structure.35 This
is in accordance with the recently established PPII propensity
of alanine in water.36-38 The third peptide, Boc-Gly-Ala-Aib-
OMe, was found to adopt a somewhat distorted 310 or type III
â-turn-like conformation.
Experiments reported in this paper were aimed at investigating
the structure of three blocked Aib-containing tripeptides, namely
Ac-Aib-Ala-Ala-OMe, Ac-Ala-Aib-Ala-OMe, and Ac-Ala-Ala-
Aib-OMe in aqueous solution. Different vibrational spectro-
scopic techniques (IR, polarized Raman, vibrational circular
1
dichroism (VCD)) were combined with ECD and H NMR
(11) Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.;, Xiong, G.; Zhang, W.;
Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman,
P. J. Comput. Chem. 2003, 24, 1999-2012.
(12) Robbins, D. J.; Stout, C. D. Proteins: Struct., Funct., Genet. 1989, 5, 289.
(13) Prasad, B. V. V.; Balaram, P. CRC Crit. ReV. Biochem. 1984, 16, 307.
(14) Augspurger, J. D.; Bindra, V. A.; Scheraga, H. A.; Kuki, A. Biochemistry
1995, 34, 2566.
(15) De Fillipis, V.; De Antoni, F.; Frigo, M.; de Laureto, P. P.; Fontana, A.
Biochemistry 1998, 37, 1686.
(16) Bosch, R.; Jung, G.; Schmitt, H.; Winter, W. Biopolymers 1995, 24, 979.
(17) Tomicolo, C.; Bonora, G. M.; Bovaso, A.; Bendetti, E.; DiBlasio, B.;
Pavone, V.; Pedone, C. J. Biomol. Struct. 1985, 3, 585.
(18) Pavone, V.; DiBasio, B.; Santini, A.; Benedetti, E.; Pedone, C. J. Mol.
Biol. 1990, 214, 633.
(19) Balarram, H.; Sukumar, M.; Balaram, P. Biopolymers 1986, 25, 2209.
(20) Karle, I. L.; Flippen-Anderson, J. L.; Sakumer, M.; Balaram, P. Int. J.
Peptide Protein Res. 1988, 32, 536.
(21) Karle, I. L.; Flippen-Anderson, J. L.; Sukumar, M.; Balaram, P. J. Med.
Chem. 1992, 35, 3885.
(22) Marshall, G. R.; Hodgkin, E. E.; Langs, D. A.; Smith, G. D.; Zabrocki, J.;
Leplawy, M. T. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 487.
(23) Blank, J. T.; Guerin, D.; Miller, S. J. Org. Lett. 2000, 2, 1248.
(24) Karle, I. L.; Sukumar, M.; Balaram, P. Proc. Natl. Acad. Sci. U.S.A. 1989,
29, 6747.
(25) DiBasio, B.; Pavone, V.; Savino, M.; Lombardi, A.; Nastri, F.; Pedone,
C.; Benedetti, E.; Crisma, M.; Anzoli, M.; Toniolo, C. J. Am. Chem. Soc.
1992, 114, 6274.
spectroscopy as well as molecular dynamics simulations.
(26) Smythe, M. L.; Huston, S. E.; Marshall, G. R. J. Am. Chem. Soc. 1993,
115, 11594.
(27) Smythe, M. L.; Huston, S. E.; Marshall, G. R. J. Am. Chem. Soc. 1995,
117, 5445.
(28) Zhang, L.; Herman, J. J. Am. Chem. Soc. 1994, 116, 11915.
(29) Schievano, E.; Bisello, A.; Chorev, M.; Bisol, A.; Mammi, S.; Peggion, E.
J. Am. Chem. Soc. 2001, 123, 2743.
(30) Bu¨rgi, R.; Daura, X.; Mark, A.; Bellanda, M.; Mammi, S.; Peggion, E.;
van Gunsteren, W. J. Peptide Res. 2001, 57, 107.
(31) Mahadevan, J.; Lee, K.-H.; Kuczera, K. J. Phys. Chem. B 2001, 105, 1863.
(32) Ponder, J. W.; Case, D. A. Force fields for protein simulations. AdV. Protein
Chem. 2003, 66, 27-85.
(33) Bosch, R.; Jung, G.; Winter, W. Liebigs Ann. Chem. 1982, 1322.
(34) Jung, G.; Bru¨ckner, H.; Bosch, R.; Winter, W.; Schaal, H.; Stra¨hle, J. Liebigs
Ann. Chem. 1983, 1096.
(35) Bosch, R.; Jung, G.; Voges, K.-P.; Winter, W. Liebigs Ann. Chem 1984,
1117.
(36) Schweitzer-Stenner, R.; Eker, F.; Griebenow, K.; Cao, X.; Nafie, L. A. J.
Am. Chem. Soc. 2004, 126, 2768.
(37) Schweitzer-Stenner, R.; Measey, T.; Kakalis, L.; Jordan, F.; Pizanelli, S.;
Forte, C.; Greibenow, K. Biochemistry 2007, 46, 1587.
(38) Schweitzer-Stenner, R.; Measey, T. J. Proc. Natl. Acad. Sci U.S.A. 2007,
104, 6649-6654.
9
13096 J. AM. CHEM. SOC. VOL. 129, NO. 43, 2007